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Type 2 diabetes is the most prevalent and serious metabolic disease all over the world, and its hallmarks are pancreatic β-cell
dysfunction and insulin resistance. Under diabetic conditions, chronic hyperglycemia and subsequent augmentation of reactive
oxygen species (ROS) deteriorate β-cell function and increase insulin resistance which leads to the aggravation of type 2 diabetes.
In addition, chronic hyperglycemia and ROS are also involved in the development of atherosclerosis which is often observed
under diabetic conditions. Taken together, it is likely that ROS play an important role in the development of type 2 diabetes and
atherosclerosis.
1. Augmentation of Reactive Oxygen
Species(ROS) by VariousPathways
under Diabetic Conditions
It has been shown that ROS are produced in various tissues
under diabetic conditions [1, 2]. There are several sources of
ROS in cells such as the nonenzymatic glycosylation reaction
[3], the electron transport chain in mitochondria [4],
and membrane-bound NADPH oxidase [5, 6]. In diabetic
animals, glycation reaction is observed in various tissues
and organs, and various kinds of glycated proteins such as
glycosylated hemoglobin, albumin, and lens crystalline are
producedinanonenzymaticalmannerthroughtheglycation
reaction. The reaction produces Schiﬀ base, Amadori prod-
uct,and ﬁnally advanced glycosylationend products (AGEs).
During the process, ROS are also produced. The electron
transport chain in mitochondria is also an important path-
way to produce ROS. Under diabetic conditions, electron
transport chain is activated, which leads to production of
larger amounts of ROS. It has been shown that membrane-
bound NADPH oxidase is also an important source of
ROS. NADPH oxidase is composed of the membrane-bound
subunits gp91 phox (Nox2)/Nox1/Nox4 and p22 phox and
thecatalyticsiteoftheoxidaseandcytosoliccomponentsp47
phox and p67 phox. NADPH oxidase is activated by various
stimulisuchasAGEs,insulin,andangiotensinII;allofwhich
are possibly induced under diabetic conditions (Figures 1(a)
and 1(b)).
2. Role of ROS in the Progression of Pancreatic
β-CellDysfunctioninType2 Diabetes
Acute exposure of β-cells to a high glucose concentration
stimulates insulin gene expression, but chronic exposure has
various adverse eﬀects on various β-cell function. However,
chronic hyperglycemia is a cause of impairment of insulin
biosynthesis and secretion. This process is called β-cell
glucose toxicity which is often observed under diabetic
conditions. In the diabetic state, hyperglycemia per se and
subsequent production of ROS decrease insulin gene expres-
sion and secretion and ﬁnally bring about apoptosis [7–28].
It has been shown that the loss of insulin gene expression is
accompanied by decreased expression and/or DNA binding
activities of transcription factors: pancreatic and duodenal
homeobox-1 (PDX-1) [19–26]a n dM a f A[ 10, 12, 15]. After
chronic exposure to a high glucose concentration, expression
and/or DNA binding activities of these two transcription
factors are reduced. It is noted here that PDX-1 plays a
crucial role in pancreas development, β-cell diﬀerentiation,
induction of surrogate β-cells, and maintenance of mature2 Mediators of Inﬂammation
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Figure 1: Augmentation of ROS by various pathways under diabetic
conditions. (a) ROS are produced by various pathways under
diabetic conditions. Hyperglycemia induces ROS through activa-
tion of the glycation reaction and electron transport chain in
mitochondria. (b) AGEs, insulin, and angiotensin II induces ROS
through activation of membrane-bound NADPH oxidase.
β-cell function [29–41] and that MafA is a recently isolated
β-cell-speciﬁc transcription factor and functions as a potent
activator of insulin gene transcription [42–47].
Underdiabeticconditions,ROSareinducedandinvolved
intheβ-cellglucosetoxicity[22–36].β-CellsexpressGLUT2,
a high-Km glucose transporter, and thereby display highly
eﬃcient glucose uptake when exposed to a high glucose
concentration. Indeed, it was shown that expressions of
ROS markers 8-hydroxy-2 -deoxyguanosine (8-OHdG) and
4-hydroxy-2, 3-nonenal (4-HNE) were increased in islets
under diabetic conditions [14, 16]. In addition, β-cells
are rather vulnerable to ROS due to the relatively low
expression of antioxidant enzymes such as catalase and
glutathione peroxidase [48, 49]. Therefore, it is likely that
ROS are involved in β-cell deterioration found in diabetes.
It was shown that when β-cell-derived cell lines or rat
isolated islets were exposed to ROS, insulin gene promoter
activity and mRNA expression were suppressed [19–26].
In addition, when they were exposed to ROS, binding of
PDX-1 and/or MafA to the insulin gene promoter was
markedly reduced. Furthermore, it was shown that the
decrease of insulin gene expression after chronic exposure
to a high glucose concentration was prevented by treatment
with antioxidants [16, 19, 25, 26]. Reduction of expression
and/or DNA binding activities of PDX-1 and MafA by
chronic exposure to high glucose was also prevented by an
antioxidant treatment. These results suggest that chronic
hyperglycemia suppresses insulin biosynthesis and secretion
by increasing ROS, accompanied by reduction of expression
and/or DNA binding activities of two important pancreatic
transcription factors: PDX-1 and MafA. Therefore, it is likely
that the alteration of such transcription factors explains, at
least in part, the suppression of insulin biosynthesis and
secretion, and thus are involved in β-cell glucose toxicity.
Indeed, it was shown that the antioxidant treatment with
N-acetyl-L-cysteine plus vitamin C and E retained glucose-
stimulated insulin secretion and moderately ameliorated
glucose tolerance in obese diabetic C57BL/KsJ-db/db mice
[19]. β-Cell mass was signiﬁcantly larger in the mice treated
with the antioxidants, and insulin content was preserved by
the antioxidant treatment. Furthermore, PDX-1 expression
was more clearly visible in the nuclei of β-cells after the
antioxidant treatment [19]. Similar eﬀects were observed
with Zucker diabetic fatty rats, another model animal for
type 2 diabetes [25]. Therefore, it is likely that antioxidant
treatment can protect β-cells against glucose toxicity. In
addition, angiotensin II type 1 receptor blocker (ARB) has
antioxidant eﬀects and thereby treatment with ARB exerts
beneﬁcial eﬀects for diabetes [50, 51]. Indeed, it was shown
that when diabetic C57BL/KsJ-db/db mice were treated with
ARB, β-cell mass and insulin content were increased, and
expressions of components of NAD(P)H oxidase and ROS
markers in β-cells were decreased. The ARB treatment also
reduced ﬁbrosis in and around the islets and prevented the
loss of endothelial cells in islets. These results suggest that
ARB treatment protects β-cells by reducing ROS and further
strengthen the hypothesis that ROS are involved in β-cell
glucose toxicity found in diabetes.
It is known that lipotoxicity is also involved in the
deterioration of β-cell function found in type 2 diabetes.
When islets or β-cell-derived cell lines were exposed to free
fatty acids (FFAs), ROS were induced, which led to the
reduction of insulin secretion and β-cell dysfunction [52–
56]. It was also reported that FFA-mediated induction of
inducible nitric oxide synthase (iNOS) and excess nitric
oxide (NO) generation were involved in the progression
of β-cell dysfunction [57]. Because intracellular NO is an
important mediator of β-cell apoptosis [58], it is likely that
the loss of β- c e l lm a s so b s e r v e di nt y p e2d i a b e t e si sd u et o
NO-induced apoptosis.
It has been suggested that activation of the c-Jun N-
terminal kinase (JNK) pathway is involved in pancreatic β-
cell dysfunction found in type 2 diabetes. It was reported
that activation of the JNK pathway is involved in reduction
of insulin gene expression by ROS and that suppression
of the JNK pathway can protect β-cells from ROS [59].
When isolated rat islets were exposed to ROS, the JNK
pathwaywasactivated,precedingthedecreaseofinsulingene
expression. Adenoviral overexpression of dominant-negative
type JNK1 (DN-JNK) protected insulin gene expression
and secretion from ROS. These results were correlated withMediators of Inﬂammation 3
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Figure 2: Role of ROS in the progression of pancreatic β-cell
dysfunction in type 2 diabetes. ROS are provoked by hyperglycemia
and/or hyperlipidemia under diabetic conditions, which leads
to activation of the JNK pathway in pancreatic β-cells. ROS
and subsequent activation of the JNK pathway induce nucleo-
cytoplasmic translocation of PDX-1, which leads to reduction of
PDX-1 activity and suppression of insulin. Therefore, it is likely
that ROS and activation of the JNK pathway are involved in β-cell
dysfunction found in type 2 diabetes.
change in the binding of PDX-1 to the insulin promoter.
Adenoviral overexpression of DN-JNK preserved PDX-1
DNA binding activity in the face of ROS, while WT-
JNK overexpression decreased PDX-1 DNA binding activity
[59]. Taken together, it is likely that activation of the JNK
pathway leads to decreased PDX-1 activity and consequent
suppression of insulin gene transcription found in the
diabetic state. Also, it was shown that PDX-1 is translocated
from the nuclei to the cytoplasm in response to ROS.
When β-cell-derived HIT cells were exposed to ROS, both
intrinsically expressed PDX-1 and exogenously introduced
green ﬂuorescent protein (GFP)-tagged PDX-1 moved from
the nuclei to the cytoplasm [60]. DN-JNK overexpression
inhibited the ROS-induced PDX-1 translocation, suggesting
that activation of the JNK pathway is involved in PDX-1
translocation by ROS. Furthermore, leptomycin B, a speciﬁc
inhibitor of the classical, leucine-rich nuclear export signal
(NES), inhibited nucleo-cytoplasmic translocation of PDX-
1 induced by ROS [60]. Taken together, it is likely that ROS
induce nucleo-cytoplasmic translocation of PDX-1 through
activationoftheJNKpathway,whichleadstoreductionofits
DNAbindingactivityandsuppressionofinsulinbiosynthesis
(Figure 2).
The forkhead transcription factor Foxo1 is known as one
of the important fundamental transcription factors playing
a key role in apoptosis, cellular proliferation and diﬀer-
entiation, and glucose metabolism through regulating the
transcription of various target genes [61, 62]. It was shown
that Foxo1 regulates hepatic gluconeogenesis, and thus con-
tributes to insulin resistance [63]. Insulin inhibits the func-
tion of Foxo1 through Akt/PKB-mediated phosphorylation
and nuclear exclusion [64], and thereby suppresses hepatic
gluconeogenesis. It was also shown that Foxo1 exhibits a
counter localization to PDX-1 in β-cells [65], suggesting
that it is involved in the deterioration of β-cell function.
Moreover, it was shown that Foxo1 plays a role as a mediator
between the JNK pathway and PDX-1 [66]. In β-cell-derived
celllineHIT-T15,Foxo1changeditsintracellularlocalization
from the cytoplasm to the nucleus after exposure to ROS.
In contrast to Foxo1, the nuclear expression of PDX-1 was
decreased and its cytoplasmic distribution was increased
by ROS. Activation of the JNK pathway also induced the
nuclear localization of Foxo1, whereas suppression of the
JNK pathway reduced the ROS-induced nuclear localization
of Foxo1, suggesting an involvement of the JNK pathway
in Foxo1 translocation [66]. In addition, ROS or activation
of the JNK pathway decreased Akt phosphorylation in HIT
cells, leading to the decreased phosphorylation of Foxo1 fol-
lowing nuclear localization. Furthermore, adenoviral Foxo1
overexpression reduced the nuclear expression of PDX-
1, whereas suppression of Foxo1 by Foxo1-speciﬁc small
interfering RNA retained the nuclear expression of PDX-
1[ 66]. Taken together, ROS and subsequent activation of
the JNK pathway induce nuclear translocation of Foxo1
through the modiﬁcation of the insulin signaling in β-cells,
whichleadstothenucleo-cytoplasmic translocationof PDX-
1 and reduction of its DNA binding activity. It was also
shown that the mammalian Ste20-like kinase 1 (MST1)
is activated by ROS, which facilitates Foxo1 translocation
from the cytoplasm to the nuclei [67]. Therefore, it is
also possible that ROS trigger Foxo1 translocation from the
cytoplasmtothenuclei,independentlyofAktactivityorAkt-
mediated phosphorylation status of Foxo1. Furthermore,
the signiﬁcance of the JNK pathway in the development
of diabetes comes from the result of a genetic analysis in
humans.Whileislet-brain-1(IB1)wasknowntosuppressthe
JNKpathway[68,69],itwasshownthatamissensemutation
withintheIB1-encodingMAPKIP1gene(S59N)isassociated
with a late onset type 2 diabetes [70]. Thus, it is likely that
activation of the JNK pathway is involved in deterioration of
β-cell function found in type 2 diabetes.
3. Role of ROS in the Progression of Insulin
ResistanceinType2Diabetes
The hallmark of type 2 diabetes is insulin resistance as well
as pancreatic β-cell dysfunction. Under diabetic conditions,
various insulin target tissues such as the liver, muscle, and fat
become resistant to insulin. The pathophysiology of insulin
resistance involves a complex network of insulin signaling
pathways. After insulin binds to insulin receptor on cell
surface, insulin receptor and its substrates are phosphory-
lated, which leads to activation of various insulin signaling
pathways [71–74]. It has been shown that ROS are involved
in the progression of insulin resistance as well as pancreatic
β-cell dysfunction [75]. Indeed, it was previously reported
thatROSdisruptedinsulin-inducedcellularredistributionof
insulin receptor substrate-1 (IRS-1) and phosphatidylinos-
itol 3-kinase (PI 3-K), and thus impaired insulin-induced
GLUT4 translocation in 3T3-L1 adipocyte [76, 77]. It was
also reported that treatment with antioxidants (N-acetyl-
L-cysteine and taurine) prevented hyperglycemia-induced
insulin resistance in vivo [78]. Furthermore, in patients with4 Mediators of Inﬂammation
type 2 diabetes, both acute and chronic administrations of
α-lipoic acid, an antioxidant, improved insulin resistance,
suggestingthatROSareinvolvedintheprogressionofinsulin
resistance [79, 80].
Under diabetic conditions, hyperglycemia increased
ROS, which presumably lead to activation of the JNK
pathway. In addition, under diabetic conditions, free fatty
acids (FFAs), various inﬂammatory cytokines (e.g., TNFα),
and endoplasmic reticulum (ER) stress are increased, which
also leads to activation of the JNK pathway. Finally, it
has been suggested that activation of the JNK pathway is
involved in insulin resistance as well as pancreatic β-cell
dysfunction found in diabetes [81, 82]. It was reported
that the JNK pathway was abnormally activated in the
liver, muscle, and adipose tissue in obese type 2 diabetic
mice and that insulin resistance in obese type 2 diabetic
mice was substantially reduced in mice homozygous for
a targeted mutation in the JNK1 gene (JNK-KO mice)
[83]. When the JNK-KO and control mice were placed
on a high-fat/high-caloric diet, blood glucose levels in the
obese JNK-KO mice were signiﬁcantly lower compared to
obese wild-type mice. Intraperitoneal insulin tolerance tests
showed that hypoglycemic response to insulin in obese wild-
type mice was lower compared to obese JNK-KO mice.
Also, intraperitoneal glucose tolerance test revealed a higher
degree of hyperglycemia in obese wild-type mice than obese
JNK-KO mice. These results indicate that the JNK-KO mice
are protected from the development of dietary obesity-
induced insulin resistance. Furthermore, targeted mutations
in JNK1 were introduced in genetically obese mice (ob/ob)
[83]. Blood glucose levels in the ob/ob-JNK-KO mice were
lower compared to ob/ob wild-type mice, and the ob/ob
wild-type mice displayed a severe and progressive hyperinsu-
linemia. Therefore, it is likely that JNK1 deﬁciency provides
resistance against obesity, hyperglycemia, and hyperinsu-
linemia in both genetic and dietary models of diabetes.
These results suggest that activation of the JNK pathway
plays an important role in the development of insulin
resistance found in type 2 diabetes. It was also reported that
overexpression of dominant-negative (DN) type JNK1 (Ad-
DN-JNK) in the liver of obese diabetic C57BL/KsJ-db/db
mice improved insulin resistance and ameliorated glucose
intolerance [83]. In intraperitoneal insulin tolerance test,
the hypoglycemic response to insulin was larger in Ad-DN-
JNK-treated db/db mice. Furthermore, in the euglycemic
hyperinsulinemic clamp test, glucose infusion rate (GIR)
in Ad-DN-JNK-treated mice was higher than that in Ad-
GFP-treated mice, indicating that suppression of the JNK
pathway in the liver reduces insulin resistance, and thus
ameliorates glucose intolerance in the db/db mice. Further-
more, hepatic glucose production (HGP) was signiﬁcantly
lower in Ad-DN-JNK-treated mice, whereas there was no
diﬀerence in the glucose disappearance rate (Rd) between
these two groups [84]. These results indicate that reduction
of insulin resistance and amelioration of glucose tolerance
by DN-JNK overexpression are mainly due to suppression
of hepatic glucose production. It has been reported that
serine phosphorylation of insulin receptor substrate-1 (IRS-
1) inhibits insulin-stimulated tyrosine phosphorylation of
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Figure 3: Role of ROS in the development of insulin resistance in
type 2 diabetes. T h eJ N Kp a t h w a yi sa c t i v a t e db yv a r i o u sf a c t o r s
such as ROS, ER stress, free fatty acids (FFAs), and inﬂammatory
cytokines such as TNFα and is involved in the development of
insulin resistance found in type 2 diabetes. It has been also shown
that the IkappaB kinase β (IKK) pathway is also activated by such
factors and is involved in the development of insulin resistance.
Therefore, it is likely that activation of stress signaling is involved
in the development of insulin resistance.
IRS-1, leading to an increase in insulin resistance [85]. IRS-1
serine307phosphorylationwasdecreasedandIRS-1tyrosine
phosphorylation was increased in Ad-DN-JNK-treated mice
[84]. Therefore, it is likely that an increase in IRS-1 serine
phosphorylation is associated with the development of
insulin resistance induced by JNK overexpression. Taken
together, suppression of the JNK pathway enhances insulin
signaling which leads to amelioration of glucose tolerance
(Figure 3).
Protein transduction domains (PTDs) such as the small
PTD from the TAT protein of human immunodeﬁciency
virus(HIV-1),theVP22proteinofHerpessimplexvirus,and
the third α-helix of the homeodomain of Antennapedia, a
Drosophila transcription factor, are known to allow various
proteins and peptides to be eﬃciently delivered into cells
through the plasma membrane, and thus there has been
increasing interest in their potential usefulness for the
delivery of bioactive proteins and peptides into cells [86–
91]. It was reported that the cell permeable JNK inhibitory
peptideiseﬀectiveforthetreatmentofdiabetes.Thispeptide
is derived from the JNK binding domain of JNK-interacting
protein-1 (JIP-1) and has been reported to function as a
dominant inhibitor of the JNK pathway [92]. It is noted here
that JIP-1 itself is a scaﬀold protein which binds JNK and
activates the JNK pathway. When this peptide was injected
intraperitoneally to C57BL/KsJ-db/db obese diabetic mice,
the FITC-conjugated peptide showed ﬂuorescence signals in
insulin target organs (liver, fat, and muscle) and in insulin
secreting tissue (pancreatic islets) [93]. In insulin tolerance
test, reduction of blood glucose levels in response to injected
insulin was larger in JNK inhibitory peptide-treated mice
[93]. Furthermore, in the euglycemic hyperinsulinemic
clamp test, the steady-state glucose infusion rate (GIR) inMediators of Inﬂammation 5
JNK inhibitory peptide-treated mice was higher than that
in untreated mice, indicating that JNK inhibitory peptide
reduces insulin resistance in the db/db mice. Endogenous
hepatic glucose production (HGP) and glucose disappear-
ance rate (Rd) in the JNK inhibitory peptide-treated mice
were also evaluated. It is noted that Rd reﬂects glucose
utilization in the peripheral tissues. HGP in JNK inhibitory
peptide-treated mice was lower than that in untreated mice.
In addition, Rd in JNK inhibitory peptide-treated mice
was higher than that in untreated mice [93]. These results
indicate that JNK inhibitory peptide treatment reduces
insulin resistance through decreasing HGP and increasing
Rd. IRS-1 serine 307 phosphorylation was decreased and
IRS-1tyrosinephosphorylationwasincreasedinthepeptide-
treated mice. Concomitantly, glucose intolerance was also
ameliorated in JNK inhibitory peptide-treated mice. Taken
together, suppression of the JNK pathway improves insulin
resistanceandamelioratesglucoseintolerance,whichfurther
strengthens the signiﬁcance of the JNK pathway in the
development of insulin resistance.
TheJNKpathwayisactivatedbyvariousfactorsincluding
ROS, ER stress, FFAs, and inﬂammatory cytokines such
as TNFα and is involved in the development of insulin
resistance found in type 2 diabetes [94–96]. It has been
shown the IkappaB kinase β (IKK) pathway is also activated
by such factors and is involved in the development of insulin
resistance [97–100]. Activation of the IKK pathway increases
IRS-1 serine phosphorylation which leads to suppression
of insulin signaling. Also, suppression of the IKK pathway
decreases insulin resistance and ameliorates glucose intoler-
ance in diabetic mice. Therefore, it is likely that activation
of stress signaling such as the JNK and IKK pathways is
involved in the development of insulin resistance and that
such pathways could be a therapeutic target for diabetes
(Figure 3).
4. Role of ROS in the Progression of
Atherosclerosis
Atherosclerosis is often observed as a macroangiopathy
under diabetic conditions. Indeed, it has been reported
that increase of intima-media thickness (IMT) in carotid
artery, an index of the progression of atherosclerosis, is
often observed in diabetic patients [101–103] and that the
progression of IMT is inﬂuenced by a variety of genetic
riskfactors[104–106] and/or intervention for diabetes [107–
109]. It is well known that hyperglycemia per se found
under diabetic conditions facilitates the progression of
atherosclerosis. In addition, hyperinsulinemia which is often
observed in subjects with insulin resistance is likely involved
in the progression of atherosclerosis.
It has been shown that ROS are induced in endothelial
cells under diabetic conditions. There are several sources
of reactive oxygen species (ROS) in cells such as the
nonenzymatic glycosylation reaction, the electron transport
chain in mitochondria, and membrane-bound NADPH
oxidase (Figure 4). It has been shown that membrane-bound
NADPH oxidase is the one of the major sources of ROS in
the vasculature and that NADPH oxidase-derived ROS play
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Figure 4: Role of ROS in the development of atherosclerosis. ROS
are produced by various pathways under diabetic conditions and
involved in the development of atherosclerosis in various aspects.
Hyperglycemia induces ROS through activation of the glycation
reaction and electron transport chain in mitochondria. Also, AGEs,
insulin, and angiotensin II induce ROS through activation of
NADPH oxidase. Increased ROS are involved in the development of
atherosclerosis in various aspects. First, ROS decrease nitric oxide
levels, which leads to endothelial cell dysfunction. Second, ROS
increase expression of various adhesion molecules such as ICAM-
1 and VCAM-1, which leads to inﬂammatory cell recruitment.
Finally, ROS increase expression of various growth factors and
activate various stress signaling such as JNK and Pim-1, which leads
to proliferation of smooth muscle cell.
a critical role in the development of atherosclerosis. NADPH
oxidase is composed of the membrane-bound subunits gp91
phox (Nox2)/Nox1/Nox4 and p22 phox, and the catalytic
site of the oxidase and cytosolic components p47 phox and
p67 phox. In vascular cells such as endothelial and smooth
muscle cells, Nox 1 and Nox 4, rather than gp91 phox,
are abundantly expressed. NADPH oxidase is activated by
various factors such as AGEs, insulin, and angiotensin II;
all of which are possibly induced under diabetic conditions
[110]. In addition, it was shown that high glucose stimulates
ROS production through the activation of NADPH oxidase
[111, 112] and that the p22 phox was signiﬁcantly increased
in rat and human diabetic arteries [113, 114]. Therefore,
it is possible that such increased expression of p22 phox
contributes to the development of atherosclerosis. It was also
reported that mice lacking p47 phox, which is an important
component for NADPH oxidase, had lower levels of aortic
ROS production compared with wild-type mice and that
when the mice were crossed with apolipoprotein E knockout
(p47 phox (−/−), apoE (−/−)) mice they had signiﬁcantly
fewer lesions in their descending aortas compared to p47
phox (+/+), apoE (−/−)m i c e[ 115]. NADPH oxidase-
derived ROS play a crucial role in the development of
atherosclerosis in human as well as in mice. Indeed, it has
beenreportedthatROSproductioninatherosclerotichuman
coronary arteries is associated with NADPH oxidase subunit
p22 phox [116]. Also, it has been reported recently that
phagocytic NADPH oxidase overactivity is involved in ROS6 Mediators of Inﬂammation
and atherosclerosis in metabolic syndrome patients and that
hyperinsulinemialikelycontributestoROSinmetabolicsyn-
drome patients through activation of NADPH oxidase [117].
In addition, it is likely that the vulnerability to oxidative
stress is determined by genetic background. There are several
enzymes regulating redox status and the vulnerability to
oxidative stress is aﬀected by genetic polymorphisms in
these enzymes. For example, it was reported that in type
2 diabetic subjects the C242T polymorphism of the p22
phox gene, an essential component of NADPH oxidase in
the vasculature, was closely associated with intima-media
thickness (IMT) of the carotid artery, an index of the
progression of atherosclerosis [105]. It is noted here that
the presence of 242T allele is known to be associated
with signiﬁcantly reduced vascular NADPH oxidase activity.
Average IMT in the diabetic subjects with the CC genotype
was signiﬁcantly higher compared to those with the TC +
TT genotypes. Furthermore, in stepwise multiple regression
analysis, p22 phox CC genotype was an independent risk
factor for increased IMT in the diabetic subjects [105]. These
results suggest that the vulnerability to oxidative stress and
the progression of atherosclerosis are inﬂuenced by genetic
background. Furthermore, the accumulation of oxidative
stress-associated gene polymorphisms is likely associated
with the severity and the progression of atherosclerosis in
diabetic patients. For example, it was reported that carotid
intima-media thickness (IMT) as well as serum 8-OHdG
level, a marker of oxidative stress, were closely associated
with the accumulation of several oxidative stress-associated
gene polymorphisms, such as the T allele of the C-588T
polymorphism in glutamate-cysteine ligase modiﬁer subunit
(GCLM) gene, the GG genotype of the G-463A polymor-
phism in myeloperoxidase (MPO) gene, the substitution of
Gln for Arg at position 192 in human paraoxonase (PON1),
and the T allele of the C242T polymorphism in NAD(P)H
oxidasep22phoxgene[118].Furthermore,theaccumulation
of these 4-gene polymorphisms was closely associated with
the progression of carotid IMT in the longitudinal settings.
In a stepwise multivariate regression analysis, the number
of prooxidant alleles was an independent risk factor for the
progression of IMT [119]. These results further support
the hypothesis that the vulnerability to oxidative stress
and the progression of atherosclerosis are inﬂuenced by
genetic background. Furthermore, it was reported that
the prevalence of myocardial infarction was signiﬁcantly
higher in the subjects with higher number of prooxidant
alleles of these 4 gene polymorphisms [120]. Therefore, it
is likely that the accumulation of oxidative stress-related
genepolymorphismsinﬂuencestheprevalenceofmyocardial
infarction as well as atherosclerosis.
Increased ROS are involved in the development of
atherosclerosis in various aspects. First, endothelial dysfunc-
tion is an early key event in atherosclerosis [121–123]. It
has been thought that ROS are involved in the progression
of endothelial cell dysfunction, which is accompanied by
inactivation of endothelial nitric oxide synthase (eNOS)
and decrease of nitric oxide (NO) levels [124]. Second,
ROS also induce expression of adhesion molecules such as
intercellular adhesion molecule-1 (ICAM-1) and vascular
adhesion molecule-1 (VCAM-1), which facilitates inﬂam-
matory cell recruitment and lipid deposition in the intimal
layer.Thesubsequentingestionofexcessoxidizedlowdensity
lipoprotein (LDL) particles by macrophages and monocytes
leads to release of various inﬂammatory cytokines and
growth factors. Finally, proliferation of vascular smooth
muscle cells (VSMCs) is a key step in the development
of atherosclerosis. It has been suggested that ROS regulate
expression of various growth factors and several growth-
related protooncogenes such as c-Myc, c-Fos and c-Jun [124,
125]. Clinical mass studies have also provided support for
the signiﬁcance of ROS in the development of atherosclerosis
[126,127].Takentogether,itislikelythatROSareinvolvedin
the VSMC proliferation and development of atherosclerosis
through various pathways (Figure 4).
The JNK pathway is known to be activated by ROS in
VSMC [128], and activation of the JNK pathway is likely
involved in the progression of atherosclerosis. It is known
thattheJNKpathwayplaysanimportantroleintheinitiation
of cellular responses, including cellular gene expression,
growth, migration, or apoptosis. It has been previously
reportedthattheJNKpathwayisactivatedinballoon-injured
arteries as well [129–131]. In vivo transfection of DN-
JNK signiﬁcantly suppressed activation of the JNK pathway
and reduced VSMC proliferation in a balloon-injury model
[132]. Neointimal formation after balloon-injury was also
prevented by DN-JNK overexpression. Bromodeoxyuridine
labeling index and total cell-counting analysis showed that
DN-JNKremarkablysuppressedVSMCproliferationinboth
the intima and the media after injury. In contrast, gene
transfer of wild-type JNK (WT-JNK) signiﬁcantly enhanced
neointimal hyperplasia after balloon-injury. Taken together,
activation of the JNK pathway triggers VSMC proliferation,
leading to neointimal formation, and the JNK pathway could
be a therapeutic target for atherosclerosis. The role of JNK in
atherosclerotic plaque formation in vivo was also examined
using atherosclerosis-prone apolipoprotein E knockout mice
(ApoE (−/−) mice). Activation of the JNK pathway was
closely correlated with the presence of clearly established
plaques in ApoE (−/−) mice with a high-cholesterol diet.
It was recently reported that atherosclerosis-prone ApoE
(−/−) mice simultaneously lacking JNK2 (ApoE (−/−),
JNK2 (−/−) mice) developed less atherosclerosis compared
to ApoE (−/−)m i c e[ 133]. Pharmacological inhibition of
the JNK activity also eﬃciently reduced plaque formation
[134].MacrophageslackingJNK2displayedsuppressedfoam
cell formation caused by defective uptake and degradation of
modiﬁed lipoproteins and showed increased amounts of the
modiﬁed lipoprotein-binding and -internalizing scavenger
receptor A (SR-A). Macrophage-restricted deletion of JNK2
was suﬃcient to decrease atherogenesis [133]. These data
suggest that JNK2-dependent phosphorylation of SR-A pro-
motes uptake of lipids in macrophages, and thereby regulates
foamcellformation.Theseresultsstrengthenthesigniﬁcance
of the JNK pathway in the progression of atherosclerosis.
Furthermore, it was shown that Pim-1, a protooncogene that
encodes a serine/threonine kinase, is also induced by ROS,
and thus is likely involved in the progression of atherosclero-
sis [135, 136]. Pim-1 was substantially induced in neointimalMediators of Inﬂammation 7
VSMC of balloon injured rat carotid arteries, and in
vivo infection with a dominant-negative Pim-1-expressing
adenovirus (Ad-DN-Pim-1) markedly suppressed neointima
formation and cell cycle progression in the balloon injured
arteries [135]. In cultured VSMC, ROS-stimulated cell cycle
progression and DNA synthesis were suppressed by DN-
Pim-1 overexpression. Furthermore, Pim-1-producing cells
were observed predominantly in the thickened intima of
human thoratic aortas and coronary arteries [135]. These
ﬁndings suggest that ROS and consequent induction of Pim-
1 expression also play an important role in the progression
of atherosclerosis. Taken together, ROS and subsequent
activation of various stress signaling such as JNK and Pim-1
are involved in the progression of atherosclerosis (Figure 4).
5. Conclusion
ROS are induced under diabetic conditions, which are
possibly involved in the progression of pancreatic β-cell
dysfunction and insulin resistance found in type 2 diabetes.
Suppression of ROS in obese type 2 diabetic mice restores β-
cell function and insulin sensitivity, leading to amelioration
of glucose intolerance. In addition, ROS are involved in
the progression of atherosclerosis which is often observed
as a macroangiopathy under diabetic conditions. Taken
together, it is likely that ROS are closely associated with the
developmentoftype2diabetesandatherosclerosis.Although
at present several clinical trials with antioxidants show only
a little eﬀect, if any, on the progression of type 2 diabetes, we
thinkthatfuturetherapywithstrongerandmoreappropriate
antioxidants would exert some beneﬁcial eﬀects on the
development of type 2 diabetes and atherosclerosis.
References
[1] J. W. Baynes and S. R. Thorpe, “Role of oxidative stress
in diabetic complications: a new perspective on an old
paradigm,” Diabetes, vol. 48, no. 1, pp. 1–9, 1999.
[2] P. Dandona, K. Thusu, S. Cook, et al., “Oxidative damage to
DNA in diabetes mellitus,” The Lancet, vol. 347, no. 8999, pp.
444–445, 1996.
[3] T. Sakurai and S. Tsuchiya, “Superoxide production from
nonenzymatically glycated protein,” FEBS Letters, vol. 236,
no. 2, pp. 406–410, 1988.
[4] M. Brownlee, “Biochemistry and molecular cell biology of
diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–
820, 2001.
[5] D.Harrison,K.K.Griendling,U.Landmesser,B.Hornig,and
H. Drexler, “Role of oxidative stress in atherosclerosis,” The
American Journal of Cardiology, vol. 91, no. 3, pp. 7A–11A,
2003.
[6] H. K. M. Mohazzab, P. M. Kaminski, and M. S. Wolin,
“NADH oxidoreductase is a major source of superoxide
anion in bovine coronary artery endothelium,” American
Journal of Physiology, vol. 266, no. 6, pp. H2568–H2572,
1994.
[7] G. C. Weir, D. R. Laybutt, H. Kaneto, S. Bonner-Weir, and A.
Sharma, “β-cell adaptation and decompensation during the
progression of diabetes,” Diabetes, vol. 50, supplement 1, pp.
S154–S159, 2001.
[ 8 ]M .P r e n t k ia n dC .J .N o l a n ,“ I s l e tβ cell failure in type 2
diabetes,” The Journal of Clinical Investigation, vol. 116, no.
7, pp. 1802–1812, 2006.
[9] V. Poitout, L. K. Olson, and R. P. Robertson, “Chronic
exposure of βTC-6 cells to supraphysiologic concentrations
of glucose decreases binding of the RIPE3b1 insulin gene
transcription activator,” The Journal of Clinical Investigation,
vol. 97, no. 4, pp. 1041–1046, 1996.
[10] V. Poitout and R. P. Robertson, “Minireview: secondary β-
cell failure in type 2 diabetes—a convergence of glucotoxicity
and lipotoxicity,” Endocrinology, vol. 143, no. 2, pp. 339–342,
2002.
[11] A. Sharma, D. Fusco-DeMane, E. Henderson, S. Efrat, and R.
Stein, “The role of the insulin control element and RIPE3b1
activators in glucose-stimulated transcription of the insulin
gene,” MolecularEndocrinology, vol.9,no.11,pp.1468–1476,
1995.
[12] A. Moran, H.-J. Zhang, L. K. Olson, J. S. Harmon, V. Poitout,
a n dR .P .R o be rt s o n ,“ Di ﬀerentiation of glucose toxicity from
beta cell exhaustion during the evolution of defective insulin
geneexpressioninthepancreaticisletcellline,HIT-T15,”The
Journal of Clinical Investigation, vol. 99, no. 3, pp. 534–539,
1997.
[13] J. L. Evans, I. D. Goldﬁne, B. A. Maddux, and G. M. Grodsky,
“Are oxidative stress-activated signaling pathways mediators
of insulin resistance and β-cell dysfunction?” Diabetes, vol.
52, pp. 1–8, 2003.
[14] S.-I. Gorogawa, Y. Kajimoto, Y. Umayahara, et al., “Probucol
preserves pancreatic β-cell function through reduction of
oxidative stress in type 2 diabetes,” Diabetes Research and
Clinical Practice, vol. 57, no. 1, pp. 1–10, 2002.
[ 1 5 ]J .S .H a r m o n ,R .S t e i n ,a n dR .P .R o b e r t s o n ,“ O x i d a t i v e
stress-mediated, post-translational loss of MafA protein as a
contributing mechanism to loss of insulin gene expression in
glucotoxicbetacells,”TheJournalofBiologicalChemistry,vol.
280, no. 12, pp. 11107–11113, 2005.
[16] Y. Ihara, S. Toyokuni, K. Uchida, et al., “Hyperglycemia
causes oxidative stress in pancreatic β-cells of GK rats, a
model of type 2 diabetes,” Diabetes, vol. 48, no. 4, pp. 927–
932, 1999.
[17] Y. Kajimoto, T. Matsuoka, H. Kaneto, et al., “Induction of
glycationsuppressesglucokinasegeneexpressioninHIT-T15
cells,” Diabetologia, vol. 42, no. 12, pp. 1417–1424, 1999.
[18] P. Maechler, L. Jornot, and C. B. Wollheim, “Hydrogen per-
oxide alters mitochondrial activation and insulin secretion in
pancreaticbetacells,”TheJournalofBiologicalChemistry,vol.
274, no. 39, pp. 27905–27913, 1999.
[19] H. Kaneto, Y. Kajimoto, J. Miyagawa, et al., “Beneﬁcial eﬀects
of antioxidants in diabetes: possible protection of pancreatic
β-cells against glucose toxicity,” Diabetes, vol. 48, no. 12, pp.
2398–2406, 1999.
[20] H. Kaneto, G. Xu, K.-H. Song, et al., “Activation of the
hexosamine pathway leads to deterioration of pancreatic β-
cell function through the induction of oxidative stress,” The
Journal of Biological Chemistry, vol. 276, no. 33, pp. 31099–
31104, 2001.
[21] H. Kaneto, T.-A. Matsuoka, Y. Nakatani, et al., “Oxidative
stress, ER stress, and the JNK pathway in type 2 diabetes,”
Journal of Molecular Medicine, vol. 83, no. 6, pp. 429–439,
2005.
[22] T.-A. Matsuoka, Y. Kajimoto, H. Watada, et al., “Glycation-
dependent, reactive oxygen species-mediated suppression of
the insulin gene promoter activity in HIT cells,” The Journal
of Clinical Investigation, vol. 99, no. 1, pp. 144–150, 1997.8 Mediators of Inﬂammation
[23] R. P. Robertson, J. Harmon, P. O. Tran, Y. Tanaka, and H.
Takahashi, “Glucose toxicity in β-cells: type 2 diabetes, good
radicals gone bad, and the glutathione connection,” Diabetes,
vol. 52, no. 3, pp. 581–587, 2003.
[24] A. P. Robertson, “Chronic oxidative stress as a central
mechanism for glucose toxicity in pancreatic islet beta cells
in diabetes,” The Journal of Biological Chemistry, vol. 279, no.
41, pp. 42351–42354, 2004.
[25] Y .T anaka,C.E.Gleaso n,P .O .T .T ran,J .S.H armo n,andR.P .
Robertson, “Prevention of glucose toxicity in HIT-T15 cells
and Zucker diabetic fatty rats by antioxidants,” Proceedings
of the National Academy of Sciences of the United States of
America , vol. 96, pp. 10857–10862, 1999.
[26] Y. Tanaka, P. O. T. Tran, J. Harmon, and R. P. Robertson,
“A role of glutathione peroxidase in protecting pancreatic β
cells against oxidative stress in a model of glucose toxicity,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, pp. 12363–12368, 2002.
[27] K. Sakai, K. Matsumoto, T. Nishikawa, et al., “Mitochondrial
reactiveoxygenspeciesreduceinsulinsecretionbypancreatic
β-cells,” Biochemical and Biophysical Research Communica-
tions, vol. 300, no. 1, pp. 216–222, 2003.
[28] H. Kaneto, J. Fujii, T. Myint, et al., “Reducing sugars trigger
oxidative modiﬁcation and apoptosis in pancreatic β-cells by
provoking oxidative stress through the glycation reaction,”
Biochemical Journal, vol. 320, no. 3, pp. 855–863, 1996.
[29] H. Ohlsson, K. Karlsson, and T. Edlund, “IPF1, a
homeodomain-containing transactivator of the insulin
gene,” EMBO Journal, vol. 12, no. 11, pp. 4251–4259, 1993.
[30] J. Leonard, B. Peers, T. Johnson, K. Ferreri, S. Lee, and M.
R. Montminy, “Characterization of somatostatin transacti-
vating factor-1, a novel homeobox factor that stimulates
somatostatin expression in pancreatic islet cells,” Molecular
Endocrinology, vol. 7, no. 10, pp. 1275–1283, 1993.
[ 3 1 ]C .P .M i l l e r ,R .E .M c G e h e eJ r . ,a n dJ .F .H a b e n e r ,“ I D X -
1: a new homeodomain transcription factor expressed in
rat pancreatic islets and duodenum that transactivates the
somatostatin gene,” EMBO Journal, vol. 13, no. 5, pp. 1145–
1156, 1994.
[32] J. Jonsson, L. Carlsson, T. Edlund, and H. Edlund, “Insulin-
promoter-factor 1 is required for pancreas development in
mice,” Nature, vol. 371, no. 6498, pp. 606–609, 1994.
[33] D. A. Stoﬀers, N. T. Zinkin, V. Stanojevic, W. L. Clarke,
and J. F. Habener, “Pancreatic agenesis attributable to a
single nucleotide deletion in the human IPF1 gene coding
sequence,” Nature Genetics, vol. 15, no. 1, pp. 106–110, 1997.
[34] U. Ahlgren, J. Jonsson, L. Jonsson, K. Simu, and H. Edlund,
“β-cell-speciﬁc inactivation of the mouse Ipf1/Pdx1 gene
results in loss of the β-cell phenotype and maturity onset
diabetes,” Genes and Development, vol. 12, no. 12, pp. 1763–
1768, 1998.
[35] S. Ferber, A. Halkin, H. Cohen, et al., “Pancreatic and
duodenal homeobox gene 1 induces expression of insulin
genes in liver and ameliorates streptozotocin-induced hyper-
glycemia,” Nature Medicine, vol. 6, no. 5, pp. 568–572, 2000.
[36] A. M. Holland, M. A. Hale, H. Kagami, R. E. Hammer,
and R. J. MacDonald, “Experimental control of pancreatic
development and maintenance,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 99,
no. 19, pp. 12236–12241, 2002.
[37] H. Noguchi, H. Kaneto, G. C. Weir, and S. Bonner-Weir,
“PDX-1 protein containing its own antennapedia-like pro-
tein transduction domain can transduce pancreatic duct and
islet cells,” Diabetes, vol. 52, no. 7, pp. 1732–1737, 2003.
[38] S. Miyazaki, E. Yamato, and J.-I. Miyazaki, “Regulated
expression of PDX-1 promotes in vitro diﬀerentiation of
insulin-producingcellsfromembryonicstemcells,”Diabetes,
vol. 53, no. 4, pp. 1030–1037, 2004.
[39] H. Kaneto, Y. Nakatani, T. Miyatsuka, et al., “PDX-1/VP16
fusion protein, together with NeuroD or Ngn3, markedly
induces insulin gene transcription and ameliorates glucose
tolerance,” Diabetes, vol. 54, no. 4, pp. 1009–1022, 2005.
[ 4 0 ]H .K a n e t o ,T .M i y a t s u k a ,T .S h i r a i w a ,e ta l . ,“ C r u c i a lr o l eo f
PDX-1 in pancreas development, β-cell diﬀerentiation, and
induction of surrogate β-cells,” Current Medicinal Chemistry,
vol. 14, no. 16, pp. 1745–1752, 2007.
[41] H. Kaneto, T. Miyatsuka, D. Kawamori, et al., “PDX-1 and
MafA play a crucial role in pancreatic β-cell diﬀerentiation
and maintenance of mature β-cell function,” Endocrine
Journal, vol. 55, pp. 235–252, 2008.
[42] M. Olbrot, J. Rud, L. G. Moss, and A. Sharma, “Identiﬁcation
of β-cell-speciﬁc insulin gene transcription factor RIPE3b1
as mammalian MafA,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 99, no. 10, pp.
6737–6742, 2002.
[43] K. Kataoka, S.-I. Han, S. Shioda, M. Hirai, M. Nishizawa,
and H. Handa, “MafA is a glucose-regulated and pancreatic
β-cell-speciﬁc transcriptional activator for the insulin gene,”
The Journal of Biological Chemistry, vol. 277, no. 51, pp.
49903–49910, 2002.
[44] T.-A. Matsuoka, L. Zhao, I. Artner, et al., “Members of
the large Maf transcription family regulate insulin gene
t r a n s c r i p t i o ni ni s l e tβ cells,” Molecular and Cellular Biology,
vol. 23, no. 17, pp. 6049–6062, 2003.
[45] T.-A. Matsuoka, I. Artner, E. Henderson, A. Means, M.
Sander, and R. Stein, “The MafA transcription factor appears
to be responsible for tissue-speciﬁc expression of insulin,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 101, no. 9, pp. 2930–2933, 2004.
[46] H. Kaneto, T.-A. Matsuoka, Y. Nakatani, et al., “A crucial
role of MafA as a novel therapeutic target for diabetes,” The
Journal of Biological Chemistry, vol. 280, no. 15, pp. 15047–
15052, 2005.
[47] T.-A. Matsuoka, H. Kaneto, R. Stein, et al., “MafA regulates
expression of genes important to islet β-cell function,”
Molecular Endocrinology, vol. 21, no. 11, pp. 2764–2774,
2007.
[48] S. Lenzen, J. Drinkgern, and M. Tiedge, “Low antioxidant
enzyme gene expression in pancreatic islets compared with
various other mouse tissues,” Free Radical Biology and
Medicine, vol. 20, no. 3, pp. 463–466, 1996.
[49] M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, “Relation
between antioxidant enzyme gene expression and antioxida-
tive defense status of insulin-producing cells,” Diabetes, vol.
46, no. 11, pp. 1733–1742, 1997.
[50] J. Shao, N. Iwashita, F. Ikeda, et al., “Beneﬁcial eﬀects of
candesartan, an angiotensin II type 1 receptor blocker, on β-
cell function and morphology in db/db mice,” Biochemical
and Biophysical Research Communications, vol. 344, no. 4, pp.
1224–1233, 2006.
[51] M.Nakayama,T.Inoguchi,T.Sonta,etal.,“Increasedexpres-
sion of NAD(P)H oxidase in islets of animal models of type 2
diabetesanditsimprovementbyanAT1receptorantagonist,”
Biochemical and Biophysical Research Communications, vol.
332, no. 4, pp. 927–933, 2005.Mediators of Inﬂammation 9
[52] C. Carlsson, L. A. H. Borg, and N. Welsh, “Sodium palmitate
induces partial mitochondrial uncoupling and reactive oxy-
gen species in rat pancreatic islets in vitro,” Endocrinology,
vol. 140, no. 8, pp. 3422–3428, 1999.
[53] J. W. Joseph, V. Koshkin, M. C. Saleh, et al., “Free fatty acid-
induced β-cell defects are dependent on uncoupling protein
2 expression,” The Journal of Biological Chemistry, vol. 279,
no. 49, pp. 51049–51056, 2004.
[54] X. Wang, H. Li, D. De Leo, et al., “Gene and protein kinase
expression proﬁling of reactive oxygen species-associated
lipotoxicity in the pancreatic β-cell line MIN6,” Diabetes, vol.
53, pp. 129–140, 2004.
[55] A. I. Oprescu, G. Bikopoulos, A. Naassan, et al., “Free
fatty acid-induced reduction in glucose-stimulated insulin
secretion: evidence for a role of oxidative stress in vitro and
in vivo,” Diabetes, vol. 56, no. 12, pp. 2927–2937, 2007.
[56] G. Bikopoulos, A. da Silva Pimenta, S. C. Lee, et al., “Ex vivo
transcriptional proﬁling of human pancreatic islets following
chronic exposure to monounsaturated fatty acids,” Journal of
Endocrinology, vol. 196, no. 3, pp. 455–464, 2008.
[57] M. Shimabukuro, M. Ohneda, Y. Lee, and R. H. Unger, “Role
of nitric oxide in obesity-induced β cell disease,” The Journal
of Clinical Investigation, vol. 100, no. 2, pp. 290–295, 1997.
[58] H. Kaneto, J. Fujii, H. G. Seo, et al., “Apoptotic cell death
triggered by nitric oxide in pancreatic β-cells,” Diabetes, vol.
44, no. 7, pp. 733–738, 1995.
[59] H. Kaneto, G. Xu, N. Fujii, S. Kim, S. Bonner-Weir, and G. C.
Weir, “Involvement of c-Jun N-terminal kinase in oxidative
stress-mediated suppression of insulin gene expression,” The
Journal of Biological Chemistry, vol. 277, no. 33, pp. 30010–
30018, 2002.
[60] D. Kawamori, Y. Kajimoto, H. Kaneto, et al., “Oxidative
stressinducesnucleo-cytoplasmictranslocationofpancreatic
transcriptionfactorPDX-1throughactivationofc-JunNH2-
terminal kinase,” Diabetes, vol. 52, no. 12, pp. 2896–2904,
2003.
[61] S.Ogg,S.Paradis,S.Gottlieb,etal.,“Theforkheadtranscrip-
tion factor DAF-16 transduces insulin-like metabolic and
longevity signals in C. elegans,” Nature, vol. 389, no. 6654,
pp. 994–999, 1997.
[62] D.AcciliandK.C.Arden,“FoxOsatthecrossroadsofcellular
metabolism, diﬀerentiation, and transformation,” Cell, vol.
117, no. 4, pp. 421–426, 2004.
[63] J. Nakae, W. H. Biggs III, T. Kitamura, et al., “Regulation
of insulin action and pancreatic β-cell function by mutated
alleles of the gene encoding forkhead transcription factor
Foxo1,” Nature Genetics, vol. 32, no. 2, pp. 245–253, 2002.
[64] W. H. Biggs III, J. Meisenhelder, T. Hunter, W. K. Cavenee,
a n dK .C .A r d e n ,“ P r o t e i nk i n a s eB / A k t - m e d i a t e dp h o s -
phorylation promotes nuclear exclusion of the winged helix
transcription factor FKHR1,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 96,
no. 13, pp. 7421–7426, 1999.
[65] T. Kitamura, J. Nakae, Y. Kitamura, et al., “The forkhead
transcription factor Foxo1 links insulin signaling to Pdx1
regulationofpancreaticβ cell growth,” TheJournalofClinical
Investigation, vol. 110, no. 12, pp. 1839–1847, 2002.
[66] D. Kawamori, H. Kaneto, Y. Nakatani, et al., “The forkhead
transcription factor Foxo1 bridges the JNK pathway and
the transcription factor PDX-1 through its intracellular
translocation,” The Journal of Biological Chemistry, vol. 281,
no. 2, pp. 1091–1098, 2006.
[67] M.K.Lehtinen,Z.Yuan,P.R.Boag,etal.,“AconservedMST-
FOXO signaling pathway mediates oxidative-stress responses
and extends life span,” Cell, vol. 125, pp. 987–1001, 2006.
[68] C. Bonny, P. Nicod, and G. Waeber, “IB1, a JIP-1-related
nuclear protein present in insulin-secreting cells,” The Jour-
nal of Biological Chemistry, vol. 273, no. 4, pp. 1843–1846,
1998.
[69] M. Dickens, J. S. Rogers, J. Cavanagh, et al., “A cytoplasmic
inhibitor of the JNK signal transduction pathway,” Science,
vol. 277, no. 5326, pp. 693–696, 1997.
[70] G. Waeber, J. Delplanque, C. Bonny, et al., “The gene
MAPK8IP1, encoding islet-brain-1, is a candidate for type 2
diabetes,” Nature Genetics, vol. 24, no. 3, pp. 291–295, 2000.
[71] G. I. Shulman, “Cellular mechanisms of insulin resistance,”
The Journal of Clinical Investigation, vol. 106, no. 2, pp. 171–
176, 2000.
[72] A. R. Saltiel and C. R. Kahn, “Insulin signalling and the
regulationofglucoseandlipidmetabolism,” Nature,vol.414,
no. 6865, pp. 799–806, 2001.
[73] T. Kadowaki, “Insights into insulin resistance and type 2
diabetes from knockout mouse models,” The Journal of
Clinical Investigation, vol. 106, no. 4, pp. 459–465, 2000.
[74] B. B. Kahn and J. S. Flier, “Obesity and insulin resistance,”
The Journal of Clinical Investigation, vol. 106, no. 4, pp. 473–
481, 2000.
[75] J. L. Evans, I. D. Goldﬁne, B. A. Maddux, and G. M. Grodsky,
“Oxidative stress and stress-activated signaling pathways: a
unifying hypothesis of type 2 diabetes,” Endocrine Reviews,
vol. 23, no. 5, pp. 599–622, 2002.
[76] A. Rudich, A. Tlrosh, R. Potashnik, R. Hemi, H. Kanety,
and N. Bashan, “Prolonged oxidative stress impairs insulin-
induced GLUT4 translocation in 3T3-L1 adipocytes,” Dia-
betes, vol. 47, no. 10, pp. 1562–1569, 1998.
[77] A. Tirosh, R. Potashnik, N. Bashan, and A. Rudich, “Oxida-
tive stress disrupts insulin-induced cellular redistribution
of insulin receptor substrate-1 and phosphatidylinositol 3-
kinase in 3T3-L1 adipocytes: a putative cellular mechanism
for impaired protein kinase B activation and GLUT4 translo-
cation,” The Journal of Biological Chemistry, vol. 274, no. 15,
pp. 10595–10602, 1999.
[78] C. A. Haber, T. K. T. Lam, Z. Yu, et al., “N-acetylcysteine and
taurine prevent hyperglycemia-induced insulin resistance in
vivo: possible role of oxidative stress,” American Journal of
Physiology, vol. 285, no. 4, pp. E744–E753, 2003.
[79] S. Jacob, P. Ruus, R. Hermann, et al., “Oral administration
of rac-α-lipoic acid modulates insulin sensitivity in patients
with type-2 diabetes mellitus: a placebo-controlled pilot
trial,” Free Radical Biology and Medicine,v o l .2 7 ,n o .3 - 4 ,p p .
309–314, 1999.
[80] T. Konrad, P. Vicini, K. Kusterer, et al., “α-lipoic acid treat-
ment decreases serum lactate and pyruvate concentrations
and improves glucose eﬀectiveness in lean and obese patients
with type 2 diabetes,” Diabetes Care, vol. 22, no. 2, pp. 280–
287, 1999.
[81] G. S. Hotamisligil, “Role of endoplasmic reticulum stress and
c-Jun NH2-terminal kinase pathways in inﬂammation and
origin of obesity and diabetes,” Diabetes, vol. 54, supplement
2, pp. S73–S78, 2005.
[82] K. E. Wellen and G. S. Hotamisligil, “Inﬂammation, stress,
and diabetes,” The Journal of Clinical Investigation, vol. 115,
no. 5, pp. 1111–1119, 2005.10 Mediators of Inﬂammation
[83] J. Hirosumi, G. Tuncman, L. Chang, et al., “A central role for
JNK in obesity and insulin resistance,” Nature, vol. 420, no.
6913, pp. 333–336, 2002.
[84] Y. Nakatani, H. Kaneto, D. Kawamori, et al., “Modulation of
the JNK pathway in liver aﬀectsinsulinresistancestatus,”The
Journal of Biological Chemistry, vol. 279, no. 44, pp. 45803–
45809, 2004.
[85] V. Aguirre, T. Uchida, L. Yenush, R. Davis, and M. F.
White, “The c-Jun NH2-terminal kinase promotes insulin
resistance during association with insulin receptor substrate-
1 and phosphorylation of Ser
307,” The Journal of Biological
Chemistry, vol. 275, no. 12, pp. 9047–9054, 2000.
[86] G.ElliottandP.O’Hare,“Intercellulartraﬃckingandprotein
delivery by a herpesvirus structural protein,” Cell, vol. 88, no.
2, pp. 223–233, 1997.
[87] A. D. Frankel and C. O. Pabo, “Cellular uptake of the tat
protein from human immunodeﬁciency virus,” Cell, vol. 55,
no. 6, pp. 1189–1193, 1988.
[88] H. Nagahara, A. M. Vocero-Akbani, E. L. Snyder, et al.,
“Transduction of full-length TAT fusion proteins into mam-
malian cells: TAT-p-27Kip1 induces cell migration,” Nature
Medicine, vol. 4, no. 12, pp. 1449–1452, 1998.
[89] H. Noguchi, M. Matsushita, T. Okitsu, et al., “A new cell-
permeable peptide allows successful allogeneic islet trans-
plantation in mice,” Nature Medicine, vol. 10, no. 3, pp. 305–
309, 2004.
[90] J. B. Rothbard, S. Garlington, Q. Lin, et al., “Conjugation
of arginine oligomers to cyclosporin A facilitates topical
delivery and inhibition of inﬂammation,” Nature Medicine,
vol. 6, no. 11, pp. 1253–1257, 2000.
[91] S. R. Schwarze, A. Ho, A. Vocero-Akbani, and S. F. Dowdy,
“Invivoproteintransduction:deliveryofabiologicallyactive
proteinintothemouse,”Science,vol.285,no.5433,pp.1569–
1572, 1999.
[92] C. Bonny, A. Oberson, S. Negri, C. Sause, and D. F.
Schorderet,“Cell-permeablepeptideinhibitorsofJNK:novel
blockers of β-cell death,” Diabetes, vol. 50, pp. 77–82, 2001.
[93] H. Kaneto, Y. Nakatani, T. Miyatsuka, et al., “Possible novel
therapy for diabetes with cell-permeable JNK-inhibitory
peptide,” Nature Medicine, vol. 10, no. 10, pp. 1128–1132,
2004.
[94] F. Urano, X. Wang, A. Bertolotti, et al., “Coupling of
stress in the ER to activation of JNK protein kinases by
transmembrane protein kinase IRE1,” Science, vol. 287, no.
5453, pp. 664–666, 2000.
[95] U. Ozcan, Q. Cao, E. Yilmaz, et al., “Endoplasmic reticulum
stress links obesity, insulin action, and type 2 diabetes,”
Science, vol. 306, no. 5695, pp. 457–461, 2004.
[96] K. E. Wellen and G. S. Hotamisligil, “Inﬂammation, stress,
and diabetes,” The Journal of Clinical Investigation, vol. 115,
no. 5, pp. 1111–1119, 2005.
[ 9 7 ]M .Y u a n ,N .K o n s t a n t o p o u l o s ,J .L e e ,e ta l . ,“ R e v e r s a lo f
obesity- and diet-induced insulin resistance with salicylates
or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535,
pp. 1673–1677, 2001.
[98] D. Cai, M. Yuan, D. F. Frantz, et al., “Local and systemic
insulin resistance resulting from hepatic activation of IKK-
β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190,
2005.
[99] M. C. Arkan, A. L. Hevener, F. R. Greten, et al., “IKK-β links
inﬂammation to obesity-induced insulin resistance,” Nature
Medicine, vol. 11, no. 2, pp. 191–198, 2005.
[100] Y. Tamura, T. Ogihara, T. Uchida, et al., “Amelioration of
glucosetolerancebyhepaticinhibitionofnuclearfactorκBin
db/db mice,” Diabetologia, vol. 50, no. 1, pp. 131–141, 2007.
[101] R.Kawamori,Y.Yamasaki,H.Matsushima,etal.,“Prevalence
of carotid atherosclerosis in diabetic patients: ultrasound
high-resolution B-mode imaging on carotid arteries,” Dia-
betes Care, vol. 15, no. 10, pp. 1290–1294, 1992.
[102] Y. Yamasaki, R. Kawamori, H. Matsushima, et al.,
“Atherosclerosis in carotid artery of young IDDM patients
monitored by ultrasound high-resolution B-mode imaging,”
Diabetes, vol. 43, no. 5, pp. 634–639, 1994.
[103] Y. Yamasaki, R. Kawamori, H. Matsushima, et al., “Asymp-
tomatic hyperglycaemia is associated with increased intimal
plus medial thickness of the carotid artery,” Diabetologia, vol.
38, no. 5, pp. 585–591, 1995.
[104] K. Aral, Y. Yamasaki, Y. Kajimoto, et al., “Association
of methylenetetrahydrofolate reductase gene polymorphism
with carotid arterial wall thickening and myocardial infarc-
tion risk in NIDDM,” Diabetes, vol. 46, no. 12, pp. 2102–
2104, 1997.
[105] R. Hayaishi-Okano, Y. Yamasaki, Y. Kajimoto, et al., “Asso-
ciation of NAD(P)H oxidase p22 phox gene variation with
advanced carotid atherosclerosis in Japanese type 2 diabetes,”
Diabetes Care, vol. 26, no. 2, pp. 458–463, 2003.
[106] Y. Yamasaki, N. Katakami, K. Sakamoto, et al., “Combination
of multiple genetic risk factors was synergistically associated
with carotid atherosclerosis in subjects with type 2 diabetes,”
Diabetes Care, vol. 29, pp. 2445–2451, 2006.
[107] N. Katakami, Y. Yamasaki, R. Hayaishi-Okano, et al., “Met-
formin or gliclazide, rather than glibenclamide, attenuate
progression of carotid intima-media thickness in subjects
with type 2 diabetes,” Diabetologia, vol. 47, no. 11, pp. 1906–
1913, 2004.
[108] Y. Yamasaki, N. Katakami, R. Hayaishi-Okano, et al., “α-
glucosidase inhibitor reduces the progression of carotid
intima-media thickness,” Diabetes Research and Clinical
Practice, vol. 67, no. 3, pp. 204–210, 2005.
[109] H. Yokoyama, N. Katakami, and Y. Yamasaki, “Recent
advances of intervention to inhibit progression of carotid
intima-media thickness in patients with type 2 diabetes
mellitus,” Stroke, vol. 37, no. 9, pp. 2420–2427, 2006.
[110] M. Ushio-Fukai, A. M. Zafari, T. Fukui, N. Ishizaka, and
K. K. Griendling, “p22phox is a critical component of the
superoxide-generating NADH/NADPH oxidase system and
regulates angiotensin II-induced hypertrophy in vascular
smoothmusclecells,”TheJournalofBiologicalChemistry,vol.
271, no. 38, pp. 23317–23321, 1996.
[111] U. Hink, H. Li, H. Mollnau, et al., “Mechanisms underlying
endothelial dysfunction in diabetes mellitus,” Circulation
Research, vol. 88, no. 2, pp. E14–E22, 2001.
[112] T. Inoguchi, P. Li, F. Umeda, et al., “High glucose level
and free fatty acid stimulate reactive oxygen species pro-
duction through protein kinase C—dependent activation of
NAD(P)H oxidase in cultured vascular cells,” Diabetes, vol.
49, no. 11, pp. 1939–1945, 2000.
[113] T. J. Guzik, S. Mussa, D. Gastaldi, et al., “Mechanisms of
increased vascular superoxide production in human diabetes
mellitus: role of NAD(P)H oxidase and endothelial nitric
oxide synthase,” Circulation, vol. 105, no. 14, pp. 1656–1662,
2002.
[114] Y. K. Kim, M.-S. Lee, S. M. Son, et al., “Vascular NADH
oxidase is involved in impaired endothelium-dependentMediators of Inﬂammation 11
vasodilation in OLETF rats, a model of type 2 diabetes,”
Diabetes, vol. 51, no. 2, pp. 522–527, 2002.
[115] P. A. Barry-Lane, C. Patterson, M. van der Merwe, et al.,
“p47phox is required for atherosclerotic lesion progression in
ApoE−/− mice,” The Journal of Clinical Investigation, vol. 108,
no. 10, pp. 1513–1522, 2001.
[116] H.Azumi,N.Inoue,Y.Ohashi,etal.,“Superoxidegeneration
in directional coronary atherectomy specimens of patients
with angina pectoris: important role of NAD(P)H oxidase,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no.
11, pp. 1838–1844, 2002.
[117] A. Fortuno, G. San Jose, M. U. Moreno, O. Beloqui, J.
Diez,andG.Zalba,“PhagocyticNADPHoxidaseoveractivity
underlies oxidative stress in metabolic syndrome,” Diabetes,
vol. 55, pp. 209–215, 2006.
[118] N. Katakami, K. Sakamoto, H. Kaneto, et al., “Combined
eﬀect of oxidative stress-related gene polymorphisms on
atherosclerosis,” Biochemical and Biophysical Research Com-
munications, vol. 379, pp. 861–865, 2009.
[119] N. Katakami, M. Saito, H. Kaneto, et al., “Combined
eﬀect of oxidative stress-related gene polymorphisms on the
progression of carotid atherosclerosis in Japanese type 2
diabetes,” Atherosclerosis, vol. 207, no. 1, pp. 29–31, 2009.
[120] N. Katakami, K. Sakamoto, H. Kaneto, et al., “Cumulative
eﬀect of oxidative stress-related gene polymorphisms on
myocardial infarction in type 2 diabetes,” Diabetes Care, vol.
32, no. 5, article e55, 2009.
[121] H. Cai and D. G. Harrison, “Endothelial dysfunction in
cardiovasculardiseases:theroleofoxidantstress,”Circulation
Research, vol. 87, no. 10, pp. 840–844, 2000.
[122] J.L.Mehta,N.Rasouli,A.K.Sinha,andB.Molavi,“Oxidative
stress in diabetes: a mechanistic overview of its eﬀects
on atherogenesis and myocardial dysfunction,” International
Journal of Biochemistry and Cell Biology,v o l .3 8 ,n o .5 - 6 ,p p .
794–803, 2006.
[123] U. Chakravarthy, R. G. Hayes, A. W. Stitt, E. McAuley, and D.
B. Archer, “Constitutive nitric oxide synthase expression in
retinalvascularendothelialcellsissuppressedbyhighglucose
and advanced glycation end products,” Diabetes, vol. 47, no.
6, pp. 945–952, 1998.
[124] N. R. Madamanchi, A. Vendrov, and M. S. Runge, “Oxidative
stress and vascular disease,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 25, no. 1, pp. 29–38, 2005.
[125] P. Delafontaine and L. Ku, “Reactive oxygen species stimulate
insulin-like growth factor I synthesis in vascular smooth
musclecells,” CardiovascularResearch,vol.33,no.1,pp.216–
222, 1997.
[126] N. G. Stephens, A. Parsons, P. M. Schoﬁeld, F. Kelly, K.
Cheeseman, and M. J. Mitchinson, “Randomised controlled
trial of vitamin E in patients with coronary disease: Cam-
bridge Heart Antioxidant Study (CHAOS),” The Lancet, vol.
347, no. 9004, pp. 781–786, 1996.
[127] J.-C. Tardif, G. Cˆ ot´ e, J. Lesp´ erance, et al., “Probucol and
multivitamins in the prevention of restenosis after coronary
angioplasty. Multivitamins and Probucol Study Group,” The
NewEnglandJournalofMedicine,vol.337,no.6,pp.365–372,
1997.
[128] M. Yoshizumi, J.-I. Abe, J. Haendeler, Q. Huang, and B. C.
Berk, “Src and Cas mediate JNK activation but not ERK1/2
and p38 kinases by reactive oxygen species,” The Journal of
BiologicalChemistry,vol.275,no.16,pp.11706–11712,2000.
[129] Y. Hu, L. Cheng, B.-W. Hochleitner, and Q. Xu, “Activation
of mitogen-activated protein kinases (ERK/JNK) and AP-
1 transcription factor in rat carotid arteries after balloon
injury,”Arteriosclerosis,Thrombosis,andVascularBiology,vol.
17, no. 11, pp. 2808–2816, 1997.
[130] S. Kim, Y. Izumi, M. Yano, et al., “Angiotensin blockade
inhibitsactivationofmitogen-activatedproteinkinasesinrat
balloon-injuredartery,”Circulation,vol.97,no.17,pp.1731–
1737, 1998.
[131] H. Koyama, N. E. Olson, F. F. Dastvan, and M. A. Reidy,
“Cell replication in the arterial wall: activation of signaling
pathway following in vivo injury,” Circulation Research, vol.
82, no. 6, pp. 713–721, 1998.
[132] Y. Izumi, S. Kim, M. Namba, et al., “Gene transfer of
dominant-negative mutants of extracellular signal-regulated
kinase and c-Jun NH2-terminal kinase prevents neointi-
mal formation in balloon-injured rat artery,” Circulation
Research, vol. 88, no. 11, pp. 1120–1126, 2001.
[133] R. Ricci, G. Sumara, I. Sumara, et al., “Requirement of JNK2
for scavenger receptor A-mediated foam cell formation in
atherogenesis,” Science, vol. 306, no. 5701, pp. 1558–1561,
2004.
[134] K. Yoshimura, H. Aoki, Y. Ikeda, et al., “Regression of
abdominal aortic aneurysm by inhibition of c-Jun N-
terminal kinase,” Nature Medicine, vol. 11, no. 12, pp. 1330–
1338, 2005.
[135] N. Katakami, H. Kaneto, H. Hao, et al., “Role of pim-1 in
smooth muscle cell proliferation,” The Journal of Biological
Chemistry, vol. 279, no. 52, pp. 54742–54749, 2004.
[136] R. Amaravadi and C. B. Thompson, “The survival kinases
Akt and Pim as potential pharmacological targets,” The
Journal of Clinical Investigation, vol. 115, no. 10, pp. 2618–
2624, 2005.